Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaxanib + Chemo in Metastatic Colorectal Cancer
NCT00021281Phase 3Unknown
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Dec 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of semaxanib in metastatic colorectal cancer (mCRC) (4 arms), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Overall Survival. Status: unknown.
02
Drugs
semaxanib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00021281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00021281.